Good morning. Today, my colleague Dani Blum writes about the intriguing promise of drugs like Ozempic. We're also covering a shooting in Russia, abortion and male kindergarten teachers. —David Leonhardt
The new panacea?
In the past two years, Ozempic has become a synonym for weight loss. When celebrities slimmed down, tabloids wondered whether they were taking the drug. Activists argued that the drug entrenched old norms about body image — people still seemed to want to be thin. Ozempic was weight loss; weight loss was Ozempic. It's like Kleenex or Scotch tape: totemic. Technically, while Ozempic is a diabetes drug, people can, and do, take it to drop weight. But the drug — and others in its class, such as Wegovy, Mounjaro and Zepbound — is about much more. Scientists believe the drugs are about to revolutionize several fields of medicine, such as cardiology and endocrinology. Researchers are also running dozens of trials to see whether they might help with Alzheimer's, liver disease, polycystic ovary syndrome and even skin conditions. If these trials prove successful, the drugs may extend many lives by years, save billions in medical costs and divide public health into before-and-after epochs. A researcher studying these drugs told me he felt like the scientist who first discovered antibiotics. Those are some sky-high hopes, and not all will be come true. But we've already seen a real-world impact. In March, the Food and Drug Administration said that doctors could use Wegovy to reduce the risk of heart problems. Last month, a trial showed that the compound in Ozempic reduced the risk of complications from chronic kidney disease. And last week, two trials found that tirzepatide, the substance in Mounjaro and Zepbound, could improve symptoms of sleep apnea. The idea that a single drug that could target so many kinds of disease might sound too good to be true. These drugs, called GLP-1s (glucagon-like peptide 1 receptor agonists), mystify even the scientists who study them. When I asked researchers how it was possible that Ozempic might help with cognitive issues and nonalcoholic fatty liver disease and opioid addiction, they gave the same answer: We don't know! But we have early clues about where these drugs might take us — and what that means for medicine. In today's newsletter, I'll explain.
Fighting inflammationSome researchers think Ozempic and drugs like it may have something of a medical superpower: lowering inflammation in the body. Inflammation is a key part of the body's defense system. When we sense a threat, such as one posed by a pathogen, our cells work to help us fight off the intruder. But chronic inflammation contributes to heart disease, lung disease, diabetes and a host of other major illnesses. If new obesity drugs really do reduce inflammation, that could explain their effect across such a wide spectrum of diseases. Still, there are already limits. Not everyone responds to GLP-1s. Even those who slim down inevitably hit a floor, typically after losing about 15 percent of their body weight. And the drugs come with side effects (nausea, vomiting, diarrhea and constipation) and rare but serious risks: People can develop gallstones and an inflamed pancreas; they can eat so little they become malnourished; and, more commonly, they can lose muscle mass. Limiting urgesWe know that these medications target the areas of the brain that regulate appetite. But there are questions around what else the drugs do to the mind. I've interviewed dozens of people taking these medications who say they've lost all interest in alcohol. Could these drugs curb other compulsive behavior, too, the way they silence "food noise"? Studies in rats suggest that GLP-1s reduce cravings for cocaine. Scientists are examining whether these medications might even be able to alleviate gambling addictions and smoking. The great experimentOzempic and drugs like it are considered "forever drugs" — that is, people are supposed to stay on them for the rest of their lives. They're like statins or blood pressure medications. When you stop taking them, they stop working.
But this class of drugs has existed for less than 20 years. Ozempic itself has been on the market for only six. We don't know what happens after lifelong use of these drugs. Researchers point to past examples of drugs we once thought were miraculous, chiefly fen-phen. It, too, was astonishingly effective for weight loss. Then doctors learned that it damaged the heart and stopped prescribing it. It will take years, more diverse trials and much more data to determine the potential of these drugs. We are years away from solid evidence underpinning their use to treat Alzheimer's disease, for instance. There's a chance they won't do what scientists hope. Researchers sometimes tell me that we're living through the great Ozempic experiment. Hundreds of thousands of people across the globe are taking GLP-1s. The number will rise as they're approved for other uses. It may be years or generations before we know their hidden limitations — or their full powers. For more
Russia Shootings
Israel-Hamas War
More International News
Abortion
Politics
Other Big Stories
Opinions The gay marriage campaign changed the law. But it didn't change many people's minds, Omar Encarnación argues. Voters need politicians' medical information to make informed choices, Dr. Daniela Lamas argues. Here are columns by Maureen Dowd on Sean Penn and David French on Clarence Thomas. Games for relaxation. Games for concentration. We have them all. For a limited time, save 50% on your first year of a New York Times Games subscription and enjoy new puzzles every day.
Role models: Boys are struggling in education. Male kindergarten teachers can help. Community: Social media is a valuable resource for gay women who come out later in life. Solstice: When the seasons turn, Stonehenge lets visitors celebrate up close. Supplements: Is fish oil helpful or harmful for the heart? Secret beaches: Cap Ferret, on France's western coast, is Paris's answer to Montauk. Locals shared some favorite spots. Metropolitan Diary: Cashing in the tattoo fund. Lives Lived: Silvano Marchetto's Greenwich Village trattoria, Da Silvano, became a star-studded canteen and a Page Six fixture over four decades. He died at 77.
W.N.B.A.: Angel Reese recorded her eighth straight double-double in the Chicago Sky's big win over Caitlin Clark and the Indiana Fever. Soccer: The U.S. men's team defeated Bolivia, 2-0, in its first game of this year's Copa América. The captain, Christian Pulisic, scored one goal and assisted on the other. N.H.L.: The Oilers and Panthers play tonight in Game 7 of the Stanley Cup Final.
How high are your socks? It's an intergenerational debate. Fashion-minded Gen Z-ers have declared a preference for crew socks, which generally rise midway up the shin, and thumbed their noses at the low-rise socks that were staples of the Millennial wardrobe. "I think part of growing up is people trying to separate themselves from what came before them," said Night Noroña, 18, who recently threw away all of his socks that hit below the ankle. Related: Want to buy taller socks? See our favorite pairs. More on culture
Pick a few ingredients off this list — maybe olives and anchovies — for a simple puttanesca. Ease your back pain by taking a walk. Resist this cute but disappointing viral oven. Take our news quiz.
Here is today's Spelling Bee. Yesterday's pangram was buoyant. And here are today's Mini Crossword, Wordle, Sudoku, Connections and Strands. Thanks for spending part of your morning with The Times. See you tomorrow. Sign up here to get this newsletter in your inbox. Reach our team at themorning@nytimes.com.
|
Gjykata e Vlorës i jep Vangjel Tavos mandatin si kryetar i Bashkisë Himarë
-
Gjykata e Vlorës i ka dhënë Vangjel Tavos mandatin si kryetar i Bashkisë së
Himarës. Vendimi është marrë një ditë më parë, 18 shtator, nga gjyqtari
Artan...
Hace 13 horas
